AGN - Allergan plc

NYSE - NYSE Delayed price. Currency in USD
171.72
-1.46 (-0.84%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous close173.18
Open170.94
Bid157.75 x 900
Ask175.33 x 800
Day's range170.48 - 172.36
52-week range142.81 - 256.80
Volume1,577,453
Avg. volume2,795,175
Market cap58.224B
Beta1.22
PE ratio (TTM)N/A
EPS (TTM)-6.30
Earnings date1 Aug 2018 - 6 Aug 2018
Forward dividend & yield2.88 (1.66%)
Ex-dividend date2018-05-17
1y target est207.00
Trade prices are not sourced from all markets
  • Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals
    Zacks4 days ago

    Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals

    Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.

  • Allergan (AGN) Presents Positive Data on Glaucoma Candidate
    Zacks5 days ago

    Allergan (AGN) Presents Positive Data on Glaucoma Candidate

    Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular hypertension.

  • GlobeNewswire5 days ago

    Detailed Research: Economic Perspectives on Stein Mart, Asbury Automotive Group, Sprint, The Kraft Heinz, Allergan plc, and Fitbit — What Drives Growth in Today's Competitive Landscape

    NEW YORK, June 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Stein ...

  • Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study
    Zacks7 days ago

    Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study

    Allergan's (AGN) anti-CGRP candidate, atogepant, successful in mid-stage study, following positive data readouts from two phase III studies on another anti-CGRP candidate, ubrogepant.

  • Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant
    Zacks11 days ago

    Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant

    Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.

  • Associated Press12 days ago

    NXP Semiconductors and Allergan rise; Smucker slips

    Stocks that moved substantially or traded heavily Thursday: J.M. Smucker Co., down $5.72 to $100.80 The packaged food company had a weak fourth quarter and gave disappointing forecasts for the current ...

  • Allergan on an upswing, Vail Resorts soars, Johnson & Johnson dips
    Yahoo Finance12 days ago

    Allergan on an upswing, Vail Resorts soars, Johnson & Johnson dips

    Allergan, Vail Resorts and Johnson & Johnson are the Yahoo Finance charts of the day.

  • Asian shares fall ahead of G7 summit, central bank meetings
    Associated Press11 days ago

    Asian shares fall ahead of G7 summit, central bank meetings

    TOKYO (AP) — Asian shares were moderately lower Friday, as investors awaited the Group of Seven leaders' meeting, continuing into the weekend, and for European Central Bank and Federal Reserve meetings next week.

  • Bloomberg13 days ago

    Icahn Builds a Small Position in Drugmaker Allergan

    Carl Icahn has built a small position in Allergan Plc, according to people familiar with the matter, as the drugmaker plans to spin off its women’s health and antibiotic divisions. Icahn previously held a position in Allergan, disclosing a stake in 2016 that was sold in the first quarter of 2017, according to data compiled by Bloomberg. Allergan rose as much as 3.3 percent in late trading in New York on the news before settling at about $159, up about 2.3 percent from Wednesday’s close.

  • How Allergan Stock Performed in May
    Market Realist13 days ago

    How Allergan Stock Performed in May

    Allergan (AGN), with headquarters in Dublin, Ireland, is one of the leading pharmaceutical companies. It deals in both generic and specialty pharmaceutical products. Its US administrative headquarters are in Parsippany, New Jersey.

  • Allergan Requests Shareholders to Veto Management Change
    Zacks13 days ago

    Allergan Requests Shareholders to Veto Management Change

    Allergan (AGN) responds to shareholders stating that it is open to the latter's opinions. However, the company has requested them to vote against appointment of independent chairman.

  • Allergan plc (NYSE:AGN): When Will It Breakeven?
    Simply Wall St.13 days ago

    Allergan plc (NYSE:AGN): When Will It Breakeven?

    Allergan plc’s (NYSE:AGN): Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The US$51.26B market-cap posted a loss in itsRead More...

  • MarketWatch14 days ago

    Activist investor Appaloosa asks Allergan for management changes

    Activist investor Appaloosa and hedge fund Senator Investment Group asked Allergan PLC for management changes early Tuesday, requesting that the company either split the office of chief executive and chairman -- two positions that Brent Saunders holds -- or get a new, outside chairman or CEO, among other options. In a letter to Allergan's board of directors, signed by Appaloosa President and Chief Executive David Tepper and Senator Investment Group Managing Partner Douglas Silverman, the financial firms described Allergan's recent strategic review as underwhelming.

  • Judges Criticize Allergan's Use of Mohawk Tribe's Sovereignty
    Bloomberg15 days ago

    Judges Criticize Allergan's Use of Mohawk Tribe's Sovereignty

    Allergan Plc faced a skeptical appeals court Monday as the company defended its use of an American Indian tribe’s sovereign immunity to avoid challenges to its patents from generic-drug makers. Two of three judges on the U.S. Court of Appeals for the Federal Circuit in Washington questioned whether Allergan was seeking to circumvent review by the Patent and Trademark Office. The reviews are widely used by technology companies, banks and insurers who say it offers a way to weed out bad patents.

  • FDA Delays Amgen-Allergan Copycat Herceptin, Gives Roche Breathing Room
    Investor's Business Daily18 days ago

    FDA Delays Amgen-Allergan Copycat Herceptin, Gives Roche Breathing Room

    Amgen and Allergan were sidelined Friday after the FDA delayed their Herceptin biosimilar, giving Roche's blockbuster breast cancer drug some breathing room.

  • Viking Therapeutics Stock Rose 101% on May 31
    Market Realist18 days ago

    Viking Therapeutics Stock Rose 101% on May 31

    On May 31, Viking Therapeutics (VKTX), a California-based biotechnology firm, closed at $9.99—a rise of ~101% from the previous day’s closing price of $4.97. The stock price nearly doubled on the news of the positive Phase-II clinical trial results from Madrigal Pharmaceuticals’ (MDGL) NASH (non-alcoholic steatohepatitis) candidate MGL-3196. The news triggered a rise of ~150% in Madrigal Pharmaceuticals’ stock price. On the same day, the SPDR S&P Biotech ETF (XBI) rose ~1.5%.

  • Allergan Won't Engage In 'Fire Sale' As It Seeks To Divest Two Units
    Investor's Business Daily20 days ago

    Allergan Won't Engage In 'Fire Sale' As It Seeks To Divest Two Units

    Botox maker Allergan is looking to sell its women's health and infectious diseases units, but it won't engage in a "fire sale" to do so, Chief Executive Brent Saunders said Wednesday.

  • Botox Maker's Puny Disposals Wouldn't Move the Needle
    Bloomberg20 days ago

    Botox Maker's Puny Disposals Wouldn't Move the Needle

    “Bold” is Allergan PLC's adjective of choice, trotted out frequently by CEO Brent Saunders and others at the Botox maker. Disposing of  two minor units won’t address broader concerns that have seen Allergan’s shares decline by more than 40 percent from last year’s highs.

  • Why Is Allergan (AGN) Down 4.1% Since its Last Earnings Report?
    Zacks20 days ago

    Why Is Allergan (AGN) Down 4.1% Since its Last Earnings Report?

    Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Allergan Recalls Taytulla Oral Contraceptives, Stock Down
    Zacks20 days ago

    Allergan Recalls Taytulla Oral Contraceptives, Stock Down

    Allergan (AGN) recalls some sample packs of Taytulla oral birth control pills. Shares decline.

  • Associated Press20 days ago

    Packaging error leads to birth control pill recall in US

    Allergan is voluntarily recalling packs of its birth control pills in the U.S. because of a packaging error with placebos, increasing the possibility of unintended pregnancy. The company says four placebo pills were placed out of order in the Taytulla packs. Allergan says the first four days of therapy had four non-hormonal placebo capsules instead of active capsules.

  • Bloomberg20 days ago

    Allergan Issues Recall After Placebos Mixed In With Birth Control Pills

    Allergan is voluntarily recalling packs of its birth control pills in the U.S. because of a packaging error with placebos, increasing the possibility of unintended pregnancy.

  • MarketWatch21 days ago

    Allergan recalls birth control that erroneously swapped placebo for contraceptive pills

    Allergan PLC is recalling one lot of the birth control Taytulla because the first four days of the therapy erroneously placed placebo pills where contraceptive capsules should have been. Patients concerned about this should consult their doctor, Allergan said. The packaging error affected one lot of Taytulla, according to Allergan, a "physicians sample pack" that was distributed nationwide.